OJU  Vol.3 No.3 , July 2013
A Prospective, Multicenter Study on Efficacy of Long-Acting Testosterone Undecanoate, If Desired in Combination with Vardenafil, in Late Onset Hypogonadal Patients with Erectile Dysfunction
Abstract: Introduction: There is substantial evidence suggesting the additive effect on erectile function (ED) of testosterone and phosphodiesterase (PDE)-5 inhibitors. But the combination of long-acting testosterone undecanoate (TU), in combination with the PDE5-I vardenafil men with with late-onset hypogonadal patients (LOH) with (ED) has not yet been studied. Aims: To evaluate the effects of TU i.m., and if desired, the PDE5i vardenafil (PDE-5I) in LOH patients with ED measured with the International Index of Erectile Function (IIEF-5). Methods: A prospective study was performed following four administrations of TU in week 0, 6, 18, 30. If no improvement of ED assessed with IIEF-5 or the Global Assessment Questionnaire (GAQ) in week 12, the PDE5 inhibitor vardenafil was added. The final evaluation was in week 46. Main Outcome Measures: Aging Male Symptom (AMS) score, IIEF-5 score, and International Prostate Symptoms Score (IPSS) at each visit were summarized as mean with standard deviation; while GAQ was summarized using frequency and percentage. Scores at each visit were also categorized into different levels of symptom severity. Results: AMS score decreased significantly at week 12, 30 and 46. IIEF-5 score increased but a significant change was found only at week 30 and 46. The GAQ assessment indicated erection and sexual intercourse already improved at the first assessment continuing thereafter. IPSS score decreased from baseline at week 46. Levels of total, free and bioavailable testosterone had increased significantly from baseline at all visits. Hematocrit, hemoglobin and prostate specific antigen increased significantly from baseline. Adverse events were rare with pain at injection site found in one patient. The two events were non-serious in type, mild in their intensity and recovered. Conclusions: Therapy with TU and, and if desired, combined with the PDE5 inhibitor vardenafil improved sexual activity in LOH patients with ED.
Cite this paper: S. Permpongkosol, K. Ratana-Olarn, A. Tantiwong, K. Tantiwongse and A. Kongkanand, "A Prospective, Multicenter Study on Efficacy of Long-Acting Testosterone Undecanoate, If Desired in Combination with Vardenafil, in Late Onset Hypogonadal Patients with Erectile Dysfunction," Open Journal of Urology, Vol. 3 No. 3, 2013, pp. 139-145. doi: 10.4236/oju.2013.33026.

[1]   S. Zona, G. Guaraldi, K. Luzi, M. Beggi, D. Santi, C. Stentarelli, et al., “Erectile Dysfunction Is More Common in Young to Middle-Aged HIV-Infected Men than in HIV-Uninfected Men,” Journal of Sexual Medicine, Vol. 9, No. 7, 2012, pp. 1923-1930. doi:10.1111/j.1743-6109.2012.02750.x

[2]   M. Maggi, J. Buvat, G. Corona, A. Guay and L. O. Torres, “Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA),” Journal of Sexual Medicine, 2012. doi:10.1111/j.1743-6109.2012.02735.x

[3]   L. Di Luigi, P. Sgro, V. Fierro, S. Bianchini, G. Battistini, V. Magini, et al., “Prevalence of Undiagnosed Testosterone Deficiency in Aging Athletes: Does Exercise Training Influence the Symptoms of Male Hypogonadism?” Journal of Sexual Medicine, Vol. 7, No. 7, 2010, pp. 2591-601.

[4]   G. Corona, G. Rastrelli, L. Vignozzi, E. Mannucci and M. Maggi, “How to Recognize Late-Onset Hypogonadism in Men with Sexual Dysfunction,” Asian Journal of Andrology, Vol. 14, No. 2, 2012, pp. 251-259. doi:10.1038/aja.2011.138

[5]   G. Corona, G. Rastrelli, A. Morelli, L. Vignozzi, E. Mannucci and M. Maggi, “Hypogonadism and Metabolic Syndrome,” Journal of Endocrinological Investigation, Vol. 34, No. 7, 2011, pp. 557-67.

[6]   N. Bassil, “Late-Onset Hypogonadism,” Medical Clinics of North America, Vol. 95, No. 3, 2011, pp. 507-523. doi:10.1016/j.mcna.2011.03.001

[7]   G. Antonini, A. Clemenzi, E. Bucci, E. De Marco, S. Morino, A. Di Pasquale, et al., “Hypogonadism in DM1 and Its Relationship to Erectile Dysfunction,” Journal of Neurology, Vol. 258, No. 7, 2011, pp. 1247-1253. doi:10.1007/s00415-011-5914-3

[8]   F. Romanelli, A. Sansone and A. Lenzi, “Erectile Dysfunction in Aging Male,” Acta Bio Medica, Vol. 81, No. S1, 2010, pp. 89-94.

[9]   J. W. Kim, M. M. Oh, M. G. Park, J. Y. Park, J. H. Bae, J. J. Kim, et al., “Combination Therapy of Testosterone Enanthate and Tadalafil on PDE5 Inhibitor Non-Reponders with Severe and Intermediate Testosterone Deficiency,” International Journal of Impotence Research, 2012.

[10]   P. Ellsworth and E. M. Kirshenbaum, “Current Concepts in the Evaluation and Management of Erectile Dysfunction,” Urologic Nursing, Vol. 28, No. 5, 2008, pp. 357-369.

[11]   A. Morelli, G. Corona, S. Filippi, S. Ambrosini, G. Forti, L. Vignozzi, et al., “Which Patients with Sexual Dysfunction Are Suitable for Testosterone Replacement Therapy?” Journal of Endocrinological Investigation, Vol. 30, No. 10, 2007, pp. 880-888.

[12]   J. Barkin, “Erectile Dysfunction and Hypogonadism (Low Testosterone),” The Canadian Journal of Urology, Vol. 18, 2011, pp. 2-7.

[13]   I. A. Smith, N. McLeod and P. Rashid, “Erectile Dysfunction—When Tablets Don’t Work,” Australian Family Physician, Vol. 39, No. 5, 2010, pp. 301-305.

[14]   A. Morales, J. Buvat, L. J. Gooren, A. T. Guay, J. M. Kaufman, H. M. Tan, et al., “Endocrine Aspects of Sexual Dysfunction in Men,” Journal of Sexual Medicine, Vol. 1, No. 1, 2004, pp. 69-81. doi:10.1111/j.1743-6109.2004.10111.x

[15]   R. Shabsigh, J. M. Kaufman, C. Steidle and H. PadmaNathan, “Randomized Study of Testosterone Gel as Adjunctive Therapy to Sildenafil in Hypogonadal Men with Erectile Dysfunction Who Do Not Respond to Sildenafil Alone,” Journal of Urology, Vol. 172, No. 2, 2004, pp. 658-663. doi:10.1097/01.ju.0000132389.97804.d7

[16]   J. Buvat, F. Montorsi, M. Maggi, H. Porst, A. Kaipia, M. H. Colson, et al., “Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study),” Journal of Sexual Medicine, Vol. 8, No. 1, 2011, pp. 284-293. doi:10.1111/j.1743-6109.2010.01956.x

[17]   A. A. Yassin and F. Saad, “Testosterone and Erectile Dysfunction,” Journal of Andrology, Vol. 29, No. 6, 2008, pp. 593-604. doi:10.2164/jandrol.107.004630

[18]   F. Saad, L. J. Gooren, A. Haider and A. Yassin, “A DoseResponse Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate,” Journal of Andrology, Vol. 29, No. 1, 2008, pp. 102-105. doi:10.2164/jandrol.107.002774

[19]   A. A. Yassin and F. Saad, “Treatment of Sexual Dysfunction of Hypogonadal Patients with Long-Acting Testosterone Undecanoate (Nebido),” World Journal of Urology, Vol. 24, No. 6, 2006, pp. 639-644. doi:10.1007/s00345-006-0120-0

[20]   R. Chatterjee, S. Wood, H. H. McGarrigle, W. R. Lees, D. J. Ralph and G. H. Neild, “A Novel Therapy with Testosterone and Sildenafil for Erectile Dysfunction in Patients on Renal Dialysis or after Renal Transplantation,” Journal of Family Planning and Reproductive Health Care, Vol. 30, No. 2, 2004, pp. 88-90. doi:10.1783/147118904322995438

[21]   G. Punzo, S. Maggi, R. Ponzio, M. Costarella and V. Gentile, “Use of Sildenafil in the Chronic Uremic Patient,” Minerva Urologica e Nefrologica, Vol. 53, No. 1, 2001, pp. 39-43.

[22]   B. F. Palmer, “Sexual Dysfunction in Uremia,” Journal of the American Society of Nephrology, Vol. 10, No. 6, 1999, pp. 1381-1388.

[23]   G. Jackson, “Sexual Dysfunction and Diabetes,” International Journal of Clinical Practice, Vol. 58, No. 4, 2004, pp. 358-362. doi:10.1111/j.1368-5031.2004.00180.x

[24]   S. Y. Kalinchenko, G. I. Kozlov, N. P. Gontcharov and G. V. Katsiya, “Oral Testosterone Undecanoate Reverses Erectile Dysfunction Associated with Diabetes Mellitus in Patients Failing on Sildenafil Citrate Therapy Alone,” The Aging Male, Vol. 6, No. 2, 2003, pp. 94-99.